Low Cost, Low Dose, Oral, Neoadjuvant Chemotherapy Protocol in Locally Advanced Borderline Oral Cancers —Feasibility Study

AbstractA vast majority of oral cancer patients in developing countries present in an advanced stage with borderline resectable/inoperable stage to busy resource-constrained tertiary cancer centers. Conventional chemotherapy protocols are associated with issues like toxicity, tolerance, cost, and compliance. The present study was conducted to assess the feasibility of low-cost home-based chemotherapy options. Single-arm feasibility study was done in borderline resectable/inoperable oral cancer patients. Home-based oral neoadjuvant chemotherapy consisting of oral methotrexate 15  mg/m2 once a week and oral celecoxib 200  mg twice daily for 8 weeks was used. RECIST Criteria 1.1 was used to assess response to therapy. The study included 60 patients. The mean age was 51.98 years with male predominance (80%). Fifty-five patients adhered to the treatment; the compliance rate is 91.60%. Affordability (Rs 700 per month ) and tolerance to therapy was 100%, and no grade III or IV toxicity was seen. Overall, 18 patients had stable disease (32.73%), partial response was seen in 15 patients (27.27%), and the disease progressed in 22 patients (40%). At the end of 8 weeks, 26 (43.3%) patients were deemed resectable. Neo adjuvant low cost, home-based metronomic chemotherapy using oral methotrexate and celecoxib seems to be a viable option in managing advanced oral cancer in resource-constrained setups.
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: Preoperative MPV, being associated with female, neoadjuvant chemotherapy, and advanced stage (Stage III and IV), may be a new prognostic factor for OS of patients with OSCC. The nomograms provided useful prediction for OS in OSCC patients. Neoadjuvant chemotherapy may improve the OS of patients with OSCC.PMID:34785954 | PMC:PMC8590944 | DOI:10.2147/CMAR.S323117
Source: Cell Research - Category: Cytology Authors: Source Type: research
ConclusionsSarcopenia is a poor prognostic indicator in lower advanced rectal cancer patients treated with CRT.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionMetformin has a significant antineoplastic effect which was measured in this study in terms of significant increase in pathological response concurrently with neoadjuvant chemotherapy in breast cancer compared to giving neoadjuvant chemotherapy alone.
Source: QJM - Category: Internal Medicine Source Type: research
ConclusionCompared to historical data, neoadjuvant autophagy inhibition with HCQ plus gemcitabine is associated with encouraging long-term survival for patients with PDAC.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presenta...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
The nation-wide study revealed that anthracycline-based chemotherapy (ABC) remained the mainstay of breast cancer treatment, especially in neo and adjuvant therapy, and was predominantly used as a combination therapy. The correlation between clinicopathological characteristics and ABC choice varied at different settings, suggesting the preference and different perspectives of medication regarding the use ABC in China. The real-world data contribute to guide the selection of the appropriate treatment and maximize the benefit of chemotherapy for patients. AbstractBackgroundAnthracycline-based chemotherapy (ABC) is one of the...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
Opinion statementThe COVID-19 pandemic forced us to rapidly and dramatically shift our medical priorities and decision making. With little literature or experience to rely on, the initial priority was to minimize patient exposure to the hospital and to others. It remains unclear whether cancer patients are at higher risk of infection or serious complications, or if it is our traditional therapies that place them to be at higher risk. By far, the greatest negative impact was on screening. Routine colonoscopies were considered elective, and as a result, delays in diagnosis will be felt for years to come. The most positive ch...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Our retrospective analysis in a large cohort of TNBC patients with residual disease after NACT confirms the benefit of adding a postoperative treatment to reduce risk of relapse and death. Based on these results, we suggest that the adjuvant therapy based on metronomic cyclophosphamide and methotrexate deserves further investigation in this patients population.PMID:34407499 | DOI:10.1016/j.breast.2021.08.004
Source: Breast - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to assess the clinical outcomes and predictive factors of neoadjuvant modified short-course radiotherapy (mSC-RT) for locally advanced rectal cancer (LARC). Data from 97 patients undergoing mSC-RT followed by radical surgery for LARC were retrospectively analyzed. A 2.5 Gy dose twice daily up to a total dose of 25 Gy in 10 fractions was administered through mSC-RT, and this was delivered with oral chemotherapy in 95 (97.9%) patients. Radical surgery was performed 6 (range, 3–13) weeks after mSC-RT. The median follow-up among surviving patients was 43 (8–86) months. All patients completed neoadj...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionSOX130 demonstrated substantial benefit for LAGC and EGJC. However, special attention should be paid to anastomotic leakage during surgery for EGJC.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Celebrex | Chemotherapy | India Health | Methotrexate | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Oral Cancer | Study | Toxicology